Prosensa Holding NV (NASDAQ:RNA) was upgraded by stock analysts at KBC Securities from a “hold” rating to an “accumulate” rating in a report issued on Wednesday. The firm currently has a $11.00 price objective on the stock, up from their previous price objective of $7.00. KBC Securities’ target price would indicate a potential upside of 1.57% from the company’s current price. Prosensa Holding NV (NASDAQ:RNA) stock performance was 5.19% in last session and finished the day at $11.56. Traded volume was 779,032.00million shares in the last session and the average volume of the stock remained 432.80K shares.
A Clarence firm has signed a deal with a Polish cigarette manufacturer to make its tobacco products for distribution in the European Union. 22nd Century Group Inc. (NYSEMKT:XXII) makes low-nicotine cigarettes for the commercial market and for government sources for smoking cessation. 22nd Century Group Inc (NYSEMKT:XXII) rose 10.83 percent to $3.48 Monday on volume of 1.08million shares. The intra-day range of the stock was $3.13 to $3.54. 22nd Century Group Inc (NYSEMKT:XXII) has a market capitalization of $204.15million.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a leading RNAi therapeutics company, announced today new pre-clinical results with its Development Candidate (DC) for ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 in development for the treatment of complement-mediated diseases. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)’s stock on June 09, 2014 reported a increase of 7.53% to the closing price of $65.96. Its fifty two weeks range is $27.98 -$112.57. The total market capitalization recorded $4.98billion. The overall volume in the last trading session was 1.18million shares. In its share capital, ALNY has 75.55million outstanding shares.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) on May 31 announced the presentation of results from a first-in-human Phase 1 study of AV-203, AVEO’s ErbB3 (HER3) inhibitory antibody candidate. Among the results, the study established a recommended Phase 2 dose of AV-203, demonstrated good tolerability and promising early signs of activity, and reached the maximum planned dose of AV-203 monotherapy. On Monday, shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) advanced 7.84% to close the day at $1.10. Company return on investment (ROI) is -116.60%. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) quarterly revenue growth is -43.01%.
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) surged 7.69% after presenting encouraging data on its oncology candidate Ad-RTS-IL-12 at the annual meeting of the American Society of Gene and Cell Therapy (:ASGCT). ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) stock performance was 1.49% in last session and finished the day at $4.08. Traded volume was 2.16million shares in the last session and the average volume of the stock remained 1.16million shares. The beta of the stock remained 2.00. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) insider ownership is 1.80%.